BioVie, Inc.

Contributing Author

Recent Articles by BioVie, Inc.

Sep-08	BioVie Announces Update to Parkinson's Phase 3 Development Program BIVI GlobeNewswire
Aug-31	BioVie Announces Completion of Treatment Phase of ADDRESS-LC Trial of Bezisterim for the Treatment of Neurological Symptoms Associated with Long COVID BIVI +5.56% GlobeNewswire
Aug-06	BioVie Announces Topline Results of Phase 2 SUNRISE-PD Trial of Bezisterim in Early Parkinson's Disease BIVI -33.82% GlobeNewswire
May-27	Join BioVie's Exclusive Live Investor Webinar and Q and A Session on June 2 BIVI GlobeNewswire
May-26	BioVie Announces Full Enrollment of the ADDRESS-LC Trial of Bezisterim for the Treatment of Neurological Symptoms Associated with Long COVID BIVI -5.26% GlobeNewswire
May-18	BioVie Announces Completion of Phase 2 SUNRISE-PD Trial in Early-Stage Parkinson's Disease BIVI GlobeNewswire
Apr-27	BioVie to Host Virtual KOL Event to Discuss the Phase 2 Study of Bezisterim for the Treatment of Parkinson's Disease ahead of Topline Data in 2Q26, on May 7, 2026 BIVI +6.00% GlobeNewswire
Apr-14	BioVie Announces Abstract Accepted for Presentation at the 2026 American Academy of Neurology Annual Meeting BIVI +5.80% GlobeNewswire
Mar-12	BioVie Announces Abstract Accepted for Presentation at AD/PD 2026 BIVI GlobeNewswire
Feb-23	Join Biovie's Exclusive Live Investor Webinar and Q&A Session on March 4 BIVI GlobeNewswire
Feb-12	BioVie Announces Abstracts Accepted for Presentation at the 2026 American College of Psychiatrists Annual Meeting BIVI GlobeNewswire
Jan-08	BioVie Completes Enrollment in Phase 2 SUNRISE-PD Trial in Early Parkinson's Disease BIVI GlobeNewswire
Nov-19	Join Biovie's Exclusive Live Investor Webinar and Q&A Session on December 9 BIVI GlobeNewswire
Sep-26	BioVie to Host Live Investor Webinar and Q&A on Oct. 8 BIVI GlobeNewswire
Aug-13	BioVie Highlighted ADDRESS-LC Phase 2 Trial Design Exploring Bezisterim for the Treatment of Neurological Symptoms of Long COVID at Keystone Symposia on Long COVID and Other Post-Acute Infection Syndromes BIVI GlobeNewswire
Aug-11	BioVie Inc. Announces Closing of $12 Million Public Offering BIVI +7.19% BIVI -6.70% GlobeNewswire
Aug-07	BioVie Inc. Announces Pricing of $12 Million Public Offering BIVI -42.61% GlobeNewswire
Jul-24	BioVie Presented Data Highlighting that Patients Treated with Bezisterim Potentially Experienced an Age Deceleration Advantage Compared to Placebo on 10 Different Biological Clocks at the 2nd World Conference on Aging and Gerontology BIVI -8.37% GlobeNewswire
Jul-22	BioVie Appoints Industry Veterans Amy Chappell, MD, FAAN, and Kameel Farag to Board of Directors BIVI +12.04% GlobeNewswire
Jul-09	BioVie Announces Data Highlighting Bezisterim's Potential to Slow or Reverse Biological Aging and Neurodegeneration Featured as a Keynote Talk at the 7th World Aging and Rejuvenation Conference BIVI GlobeNewswire
Jun-26	BioVie Highlights Patient-Centric Design of SUNRISE-PD Trial at Advanced Therapeutics in Movement & Related Disorders Congress (ATMRD) BIVI GlobeNewswire
Jun-24	BioVie to Present Overview of Phase 2 SUNRISE-PD Trial at the Advanced Therapeutics in Movement & Related Disorders Congress BIVI +5.94% GlobeNewswire
May-15	BioVie Enrolls First Patient in ADDRESS-LC Clinical Trial Assessing Novel Anti-Inflammatory Candidate Bezisterim for the Treatment of Neurological Symptoms Associated with Long COVID BIVI GlobeNewswire
May-14	BioVie to Host Virtual KOL Event to Discuss the Phase 2 Study of Bezisterim for the Treatment of Parkinson's Disease on May 28, 2025 BIVI GlobeNewswire
May-07	BioVie to Present Rationale and Design of Phase 2 SUNRISE-PD Clinical Trial at the 30th World Congress on Parkinson's Disease and Related Disorders (IAPRD 2025) BIVI -6.90% GlobeNewswire
May-05	BioVie Unveils Corporate Advisory Board Featuring Neuralink Co-Founder, Former Executives from Mastercard and Apple, and High-Impact Industry Leaders to Advance BioVie Mission and Growth BIVI -5.79% GlobeNewswire

BioVie, Inc.

Recent Articles by BioVie, Inc.

Upgrade your Finviz experience